



ASX RELEASE

Peplin Moves Office

BRISBANE, Australia, June 25, 2004: Peplin Biotech Ltd (ASX: PEP) today announced that it is relocating its head office within Brisbane with effect from 28 June 2004.

The new address and telephone numbers from 28 June are:

Level 2, Brisbane Portal,
1 Breakfast Creek Road,
NEWSTEAD
QLD 4006

Telephone: 07 - 3250 1200
Facsimile: 07 - 3250 1299

ABOUT PEPLIN BIOTECH

Peplin Biotech Ltd is focused on the discovery, development and commercialisation of prescription human therapeutic products for the treatment of cancer and other diseases which have limited therapeutic options. Peplin's strategy is to leverage its pipeline of novel proprietary products through collaborative development and commercialisation arrangements with international pharmaceutical companies. Peplin's lead product is a potential topical therapy for actinic keratosis and non-melanoma skin cancer. It is the subject of a joint development agreement with Allergan, Inc. of Irvine, California for commercialisation in North and South America.

Peplin's earlier stage pipeline is targeted at bladder cancer using PEP005 in an intra-cavity formulation (PEP005 IC) and leukaemia using an intra-venous formulation (PEP005 IV). Its new portfolio of EPUFA compounds opens additional potential opportunities in cancer and adds candidates for cardiovascular disease, pain, inflammation and diabetic complications.

Further information on Peplin:

Michael Aldridge
Tel: 07-3854-0980
michael.aldrige@peplin.com

Peplin Biotech Ltd ABN 55 090 819 275

Ground Floor, South Tower, Terrace Office Park, 527 Gregory Terrace, Bowen Hills, Queensland 4006, Australia.

Tel: 61-7-3854 0980

Fax: 61-7-3854 0989

www.peplin.com